

9 September 2025

Almac Group Expands Bioavailability Enhancement Capabilities *Addressing a critical need in drug development*

Almac Group has completed a multi-million-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK.

The significant investment by Almac Pharma Services, will address ongoing industry challenges around solubility and growing global demand for advanced formulation solutions. The investment includes the installation of Buchi S300 and GEA PSD1 closed-loop spray drying technology and extensive expansion of the facility's analytical laboratories.

This new technology, coupled with existing liquid capsule filling and non-sterile oral liquid formulation solutions at the facility, widens Almac's bioavailability enhancement capability. The new technologies' containment capabilities also complement existing potent-handling capabilities at the site.

This latest clinical investment expands on Almac's long-standing pre-clinical expertise in bioavailability and amorphous solid dispersion development using a range of technologies including spray drying and melt extrusion. Almac also offers advanced particle engineering technologies and supporting analytical capabilities.

This expansion of market-leading technologies and expertise across Almac's scientific teams now bridges the gap between pre-clinical and clinical drug development and gives clients even greater access to a range of advanced formulation approaches. This results in delivering a faster route to market for our clients, improved therapeutic performance and ultimately better patient outcomes.

James Hurst, VP Operations and Charnwood Site Head, Almac Pharma Services said: "This investment is a direct response to the growing demand for sophisticated formulation solutions. Spray drying is a cornerstone technology for enabling next-generation therapeutics, and our expanded capabilities ensure we remain at the forefront of pharmaceutical innovation. Our clients trust us to deliver precision, speed, and scientific excellence – this investment reflects our ongoing commitment to supporting clients with advanced technologies and expertise that drive success."

This latest announcement builds upon the Group's £11m investment in global analytical capabilities and comes just months after Almac Pharma Services officially opened its 100,000 square foot commercial manufacturing facility at its global headquarters in Craigavon, Northern Ireland. The £65 million facility further strengthens Almac's end-to-end service offering, reinforcing the company's ongoing commitment to expanding capacity, advancing technological innovation, and supporting clients worldwide with industry-leading pharmaceutical development and manufacturing solutions.

ENDS

About Almac Sciences

Almac Sciences delivers services from development to commercial scale of advanced intermediates & Active Pharmaceutical Ingredients (API) for small molecules (including highly potent) and peptides. The company has a proven track record of saving time & costs through the integration of services & application of innovative biocatalysis & technology solutions.



Supported by expert radiolabelling, physical sciences and global analytical services teams, think Almac for drug development outsourcing solutions.

About Almac Pharma Services

With over 55 years' experience, Almac Pharma Services is an established, reliable and world leading outsourcing partner to the global pharmaceutical and biotechnology industry.

Employing over 1,800 highly skilled individuals across 4 locations across the UK, Europe and the US, the company provides tailored, quality-led and timely solutions from early and late phase pharmaceutical development, clinical and commercial drug product manufacture, product launch through to commercial packaging and global distribution.

Currently supporting client portfolios across more than 70 countries, the company's fully integrated, end-to-end solutions are tailored to meet the needs of clients' unique products and their patients.

About Almac Group

A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.

Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 7,700 highly skilled personnel across 18 facilities including Europe, the US and Asia.

To keep up to date with latest news, follow us on [X](#) and [LinkedIn](#) or visit amacgroup.com.

